These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33309833)

  • 21. The present state of the art in expression, production and characterization of monoclonal antibodies.
    Gaughan CL
    Mol Divers; 2016 Feb; 20(1):255-70. PubMed ID: 26299798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies.
    Schenck L; Erdemir D; Saunders Gorka L; Merritt JM; Marziano I; Ho R; Lee M; Bullard J; Boukerche M; Ferguson S; Florence AJ; Khan SA; Sun CC
    Mol Pharm; 2020 Jul; 17(7):2232-2244. PubMed ID: 32392068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
    Zhuang Y; Chen D; Sharma A; Xu Z
    AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing.
    Burcham CL; Florence AJ; Johnson MD
    Annu Rev Chem Biomol Eng; 2018 Jun; 9():253-281. PubMed ID: 29879381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
    Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
    J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput process development for biopharmaceutical drug substances.
    Bhambure R; Kumar K; Rathore AS
    Trends Biotechnol; 2011 Mar; 29(3):127-35. PubMed ID: 21255855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous flow technology vs. the batch-by-batch approach to produce pharmaceutical compounds.
    Cole KP; Johnson MD
    Expert Rev Clin Pharmacol; 2018 Jan; 11(1):5-13. PubMed ID: 29206489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade
    Melsheimer R; Calmann M; DeRitis A; Philip V; Van Gog F; Doolittle L; Goyal K; Neblock D
    BioDrugs; 2018 Oct; 32(5):405-414. PubMed ID: 30143982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives.
    Grangeia HB; Silva C; Simões SP; Reis MS
    Eur J Pharm Biopharm; 2020 Feb; 147():19-37. PubMed ID: 31862299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and future issues in the manufacturing and development of monoclonal antibodies.
    Kozlowski S; Swann P
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):707-22. PubMed ID: 16828921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review.
    Tomba E; Facco P; Bezzo F; Barolo M
    Int J Pharm; 2013 Nov; 457(1):283-97. PubMed ID: 24016743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.